{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:22:53Z","timestamp":1770960173343,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,28]]},"DOI":"10.7759\/cureus.100276","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:59:51Z","timestamp":1766969991000},"source":"Crossref","is-referenced-by-count":1,"title":["Amyloid Positron Emission Tomography Imaging at the Onset of Amyloid-Related Abnormalities With Edema in an Alzheimer\u2019s Disease Patient"],"prefix":"10.7759","author":[{"given":"Heii","family":"Arai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Aiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Guidelines for the Promotion of Appropriate Use-Donanemab (Recombinant) (Article in Japanese)","author":"Ministry of Health","year":"2024","unstructured":"Ministry of Health, Labour and Welfare. Guidelines for the Promotion of Appropriate Use-Donanemab (Recombinant) (Article in Japanese). Tokyo, Japan; 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack CR Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, et al.. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018, 14:535-62. 10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck CH","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al.. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023, 388:9-21. 10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun MA","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, et al.. Donanemab in early Alzheimer's disease. N Engl J Med. 2021, 384:1691-704. 10.1056\/NEJMoa2100708","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug development in Alzheimer\u2019s disease: the path to 2025","volume":"8","author":"Cummings J","year":"2016","unstructured":"Cummings J, Aisen PS, DuBois B, et al.. Drug development in Alzheimer\u2019s disease: the path to 2025. Alzheimers Res Ther. 2016, 8:39. 10.1186\/s13195-016-0207-9","journal-title":"Alzheimers Res Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in two phase 3 studies evaluating aducanumab in patients with early Alzheimer\u2019s disease","volume":"79","author":"Salloway S","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, et al.. Amyloid-related imaging abnormalities in two phase 3 studies evaluating aducanumab in patients with early Alzheimer\u2019s disease. JAMA Neurol. 2022, 79:13-21. 10.1001\/jamaneurol.2021.4161","journal-title":"JAMA Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling RA","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, et al.. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011, 7:367-85. 10.1016\/j.jalz.2011.05.2351","journal-title":"Alzheimers Dement"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.016990","article-title":"Diagnosis of cerebral amyloid angiopathy: Evolution of the Boston criteria","volume":"49","author":"Greenberg SM","year":"2018","unstructured":"Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: Evolution of the Boston criteria. Stroke. 2018, 49:491-97. 10.1161\/STROKEAHA.117.016990","journal-title":"Stroke"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein MF","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12:189-198. 10.1016\/0022-3956(75)90026-6","journal-title":"J Psychiatr Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.43.11.2412-a","article-title":"The clinical dementia rating (CDR): current version and scoring rules","volume":"43","author":"Morris JC","year":"1993","unstructured":"Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993, 43:2412-14. 10.1212\/wnl.43.11.2412-a","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.96751","article-title":"MRI-Based medial temporal atrophy may reflect amyloid pet positivity in cognitively normal individuals: a preliminary study","volume":"17","author":"Arai H","year":"2025","unstructured":"Arai H. MRI-Based medial temporal atrophy may reflect amyloid pet positivity in cognitively normal individuals: a preliminary study. Cureus. 2025, 17:e96751. 10.7759\/cureus.96751","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk WE","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, et al.. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015, 11:1-15.e1-4. 10.1016\/j.jalz.2014.07.003","journal-title":"Alzheimers Dement"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny J","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, et al.. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease. Nature. 2016, 537:50-56. 10.1038\/nature19323","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein S","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, et al.. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022, 9:197-210. 10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1153305","article-title":"Amyloid and tau PET in cerebral amyloid angiopathy-related inflammation two case reports and literature review","volume":"14","author":"Yang JY","year":"2023","unstructured":"Yang JY, Chu YT, Tsai HH, Jeng JS. Amyloid and tau PET in cerebral amyloid angiopathy-related inflammation two case reports and literature review. Front Neurol. 2023, 14:1153305. 10.3389\/fneur.2023.1153305","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.204180","article-title":"Cerebral amyloid angiopathy related inflammation: three case reports and a review","volume":"82","author":"Chung KK","year":"2011","unstructured":"Chung KK, Anderson NE, Hutchinson D, Synek B, Barber PA. Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry. 2011, 82:20-26. 10.1136\/jnnp.2009.204180","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A7586","article-title":"Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice","volume":"43","author":"Cogswell PM","year":"2022","unstructured":"Cogswell PM, Barakos JA, Barkhof F, et al.. Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol. 2022, 43:E19-35. 10.3174\/ajnr.A7586","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel H","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JA, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023, 146:4414-24. 10.1093\/brain\/awad188","journal-title":"Brain"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251361051","article-title":"Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease","volume":"107","author":"Arai H","year":"2025","unstructured":"Arai H, Aiba S, Arai R. Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease. J Alzheimers Dis. 2025, 107:494-95. 10.1177\/13872877251361051","journal-title":"J Alzheimers Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association","volume":"9","author":"Johnson KA","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, et al.. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 2013, 9:e-1-16. 10.1016\/j.jalz.2013.01.002","journal-title":"Alzheimers Dement"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/444276-amyloid-positron-emission-tomography-imaging-at-the-onset-of-amyloid-related-abnormalities-with-edema-in-an-alzheimers-disease-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:59:53Z","timestamp":1766969993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/444276-amyloid-positron-emission-tomography-imaging-at-the-onset-of-amyloid-related-abnormalities-with-edema-in-an-alzheimers-disease-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.100276","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,28]]}}}